Patents by Inventor Alexey Teplyakov

Alexey Teplyakov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MATERIALS AND METHODS FOR IMPROVED SINGLE CHAIN VARIABLE FRAGMENTS
    Publication number: 20240067754
    Abstract: Disclosed are materials and methods for improved single chain variable fragments.
    Type: Application
    Filed: September 5, 2023
    Publication date: February 29, 2024
    Inventors: Jinquan LUO, Lauren BOUCHER, Michael FELDKAMP, Michael DIEM, Anthony A. ARMSTRONG, Alexey TEPLYAKOV, Chichi HUANG
  • Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
    Patent number: 11884722
    Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: January 30, 2024
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoldo L. Luistro, III, Diana Chin
  • Materials and methods for improved single chain variable fragments
    Patent number: 11787875
    Abstract: Disclosed are materials and methods for improved single chain variable fragments.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: October 17, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Jinquan Luo, Lauren Boucher, Michael Feldkamp, Michael Diem, Anthony A. Armstrong, Alexey Teplyakov, Chichi Huang
  • Neutralizing human anti-CD27 antibodies
    Patent number: 11732050
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: August 22, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF
    Publication number: 20230227548
    Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
    Type: Application
    Filed: January 20, 2023
    Publication date: July 20, 2023
    Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoido Luistro, Diana Chin
  • Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
    Patent number: 11685777
    Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: June 27, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoldo L. Luistro, III, Diana Chin
  • ANTI-CCL17 ANTIBODIES
    Publication number: 20220348647
    Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: June 29, 2022
    Publication date: November 3, 2022
    Inventors: Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
  • Nucleic acids encoding anti-CD154 antibodies
    Patent number: 11421037
    Abstract: The present invention relates to antagonistic antibodies specifically binding CD154, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: August 23, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Johan Fransson, Galina Obmolova, Anish Suri, Fang Teng, Alexey Teplyakov, Hong Zhou, Jocelyn Leu
  • Anti-CCL17 antibodies
    Patent number: 11414484
    Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: August 16, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
  • GM-CSF variants and methods of use
    Patent number: 11208450
    Abstract: GM-CSF variants, polynucleotides encoding them, and methods of making and using the foregoing are useful in treatment of immune-related disorders, such as inflammatory bowel disease (IBD).
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: December 28, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Thomas Rutkoski, Alexey Teplyakov, Nicole Wunderler
  • MATERIALS AND METHODS FOR IMPROVED SINGLE CHAIN VARIABLE FRAGMENTS
    Publication number: 20210047435
    Abstract: Disclosed are materials and methods for improved single chain variable fragments.
    Type: Application
    Filed: August 14, 2020
    Publication date: February 18, 2021
    Inventors: Jinquan Luo, Lauren Boucher, Michael Feldkamp, Michael Diem, Anthony A. Armstrong, Alexey Teplyakov, Chichi Huang
  • ANTI-CCL17 ANTIBODIES
    Publication number: 20210017267
    Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 21, 2021
    Inventors: Ken BOAKYE, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
  • Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
    Patent number: 10844122
    Abstract: Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: November 24, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Glenn Anderson, Rosa Cardoso, Michael Diem, Francois Gaudet, Shalom Goldberg, Benjamin Harman, Linus Hyun, Steven Jacobs, Donna Klein, Yingzhe Li, Jinquan Luo, Ronan McDaid, Jill Mooney, Jennifer Nemeth-Seay, Karyn O'Neil, Steven Pomerantz, Galla Chandra Rao, Tracy Spinka-Doms, Alexey Teplyakov, Leopoldo Luistro, Sheng-Jiun Wu
  • Anti-CCL17 antibodies
    Patent number: 10829549
    Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: November 10, 2020
    Assignee: Jannsen Biotech, Inc.
    Inventors: Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
  • ANTI-CD154 ANTIBODIES AND METHODS OF USING THEM
    Publication number: 20200317794
    Abstract: The present invention relates to antagonistic antibodies specifically binding CD154, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: April 21, 2020
    Publication date: October 8, 2020
    Inventors: Johan Fransson, Galina Obmolova, Anish Suri, Fang Teng, Alexey Teplyakov, Hong Zhou, Jocelyn Leu
  • Human Anti-CD27 Antibodies
    Publication number: 20200277393
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies
    Patent number: 10689453
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: June 23, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Anti-CD154 antibodies and methods of using them
    Patent number: 10669343
    Abstract: The present invention relates to antagonistic antibodies specifically binding CD154, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: June 2, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Johan Fransson, Galina Obmolova, Anish Suri, Fang Teng, Alexey Teplyakov, Hong Zhou, Jocelyn Leu
  • GM-CSF Variants and Methods of Use
    Publication number: 20200148736
    Abstract: GM-CSF variants, polynucleotides encoding them, and methods of making and using the foregoing are useful in treatment of immune-related disorders, such as inflammatory bowel disease (IBD).
    Type: Application
    Filed: January 17, 2020
    Publication date: May 14, 2020
    Inventors: Thomas Rutkoski, Alexey Teplyakov, Nicole Wunderler
  • GM-CSF variants and methods of use
    Patent number: 10562948
    Abstract: GM-CSF variants, polynucleotides encoding them, and methods of making and using the foregoing are useful in treatment of immune-related disorders, such as inflammatory bowel disease (IBD).
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: February 18, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Thomas Rutkoski, Alexey Teplyakov, Nicole Wunderler